Codagenix Overview
- Year Founded
-
2011

- Status
-
Private
- Employees
-
27

- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$25M
- Investors
-
11
Codagenix General Information
Description
Developer of live-attenuated viral vaccine design technology designed to provide target antigens placed in an attenuated backbone virus. The company's vaccines use synthetic attenuated virus engineering, which is based on synthetic biology and is re-designed for the entire genome to yield a vaccine strain, enabling the healthcare industry with viral vaccines to treat influenza, dengue, polio, and other diseases.
Contact Information
Website
www.codagenix.comCorporate Office
- 3 Bioscience Park Drive
- Farmingdale
- New York, NY 11735
- United States
Corporate Office
- 3 Bioscience Park Drive
- Farmingdale
- New York, NY 11735
- United States
Codagenix Timeline
Codagenix Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
18. Later Stage VC (Series B) | 10-Feb-2023 | $25M | Completed | Clinical Trials - Phase 3 | ||
17. Later Stage VC (Series B) | 28-Jun-2022 | Completed | Clinical Trials - Phase 3 | |||
16. Later Stage VC (Series B) | 14-Oct-2021 | Completed | Clinical Trials - Phase 3 | |||
15. Grant | 06-May-2021 | Completed | Clinical Trials - Phase 3 | |||
14. Later Stage VC (Series B) | 18-Mar-2021 | Completed | Clinical Trials - Phase 3 | |||
13. Grant | 22-Jul-2020 | Completed | Clinical Trials - Phase 3 | |||
12. Later Stage VC (Series B) | 10-Jan-2020 | Completed | Clinical Trials - Phase 3 | |||
11. Grant | 31-Dec-2017 | Completed | Clinical Trials - Phase 3 | |||
10. Later Stage VC | 12-Oct-2017 | $1.4M | $5.5M | Completed | Clinical Trials - Phase 3 | |
9. Grant | 16-Aug-2017 | $809K | $4.1M | Completed | Clinical Trials - Phase 3 |
Codagenix Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A5 | ||||||||
Series A4 | ||||||||
Series A3 | ||||||||
Series A2 | 3,619,189 | $0.000010 | 6% | $0.55 | $0.55 | 1x | $0.55 | 12.47% |
Series A1 | 187,266 | $0.000010 | 6% | $0.27 | $0.27 | 1x | $0.27 | 0.65% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Codagenix Comparisons
Industry
Financing
Details
Codagenix Competitors (3)
One of Codagenix’s 3 competitors is Vyriad, a Venture Capital-Backed company based in Rochester, MN.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Vyriad | Venture Capital-Backed | Rochester, MN | ||||
Candel Therapeutics | Formerly VC-backed | Needham, MA | ||||
Dynavax Technologies | Formerly VC-backed | Emeryville, CA |
Codagenix Patents
Codagenix Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20250025547-A1 | Parenterally administrable influenza vaccine and uses thereof | Pending | 02-Dec-2021 | ||
AU-2022306850-A1 | Deoptimized sars-cov-2 variants and methods and uses thereof | Pending | 07-Jul-2021 | ||
AU-2022307684-A1 | Deoptimized yellow fever virus and methods and uses thereof | Pending | 07-Jul-2021 | ||
CA-3229050-A1 | Deoptimized sars-cov-2 variants and methods and uses thereof | Pending | 07-Jul-2021 | ||
CA-3223214-A1 | Deoptimized yellow fever virus and methods and uses thereof | Pending | 07-Jul-2021 | A61K39/12 |
Codagenix Signals
Codagenix Investors (11)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Adjuvant Capital | Impact Investing | Minority | ||
Euclidean Capital | Family Office | Minority | ||
In-Q-Tel | Not-For-Profit Venture Capital | Minority | ||
Serum Institute of India | PE-Backed Company | Minority | ||
Topspin Consumer Partners | PE/Buyout | Minority |
Codagenix FAQs
-
When was Codagenix founded?
Codagenix was founded in 2011.
-
Where is Codagenix headquartered?
Codagenix is headquartered in New York, NY.
-
What is the size of Codagenix?
Codagenix has 27 total employees.
-
What industry is Codagenix in?
Codagenix’s primary industry is Drug Discovery.
-
Is Codagenix a private or public company?
Codagenix is a Private company.
-
What is Codagenix’s current revenue?
The current revenue for Codagenix is
. -
How much funding has Codagenix raised over time?
Codagenix has raised $56M.
-
Who are Codagenix’s investors?
Adjuvant Capital, Euclidean Capital, In-Q-Tel, Serum Institute of India, and Topspin Consumer Partners are 5 of 11 investors who have invested in Codagenix.
-
Who are Codagenix’s competitors?
Vyriad, Candel Therapeutics, and Dynavax Technologies are competitors of Codagenix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »